Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 17 bp deletion in exon1.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-HPSE, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Heparanase 1 also known as HPA1 or HPSE is an endo-β-D-glucuronidase enzyme with a molecular mass of approximately 50 kDa. It functions mechanically by cleaving heparan sulfate (HS) chains which are long sugar chains found on the extracellular matrix and cell surfaces. This cleavage activity remodels the matrix and influences cell behavior. Heparanase 1 is mainly expressed in the placenta lymphoid tissues and various tumor cells where it plays a role in matrix degradation and cell migration.
Biological function summary
When heparan sulfate is cleaved by Heparanase 1 it causes the release of HS-bound growth factors and cytokines making them available to cells. This enzymatic activity facilitates cell proliferation and angiogenesis affecting processes important for tissue repair and cancer progression. Heparanase 1 does not require a complex for its function but operates as a monomeric enzyme. Its activity is investigated using assays like heparanase activity assays or ELISA for measuring the enzyme's activity in different biological contexts including mouse models.
Pathways
The activity of Heparanase 1 intersects significantly with the regulation of angiogenesis and cell signaling pathways such as the VEGF and FGF pathways. These pathways are important for new blood vessel formation making them significant in both normal development and cancer. Heparanase 1 interacts with proteins such as VEGF which is important for blood vessel growth and integrins which are involved in cell-matrix interactions and signaling.
Heparanase 1 is associated with tumor metastasis and inflammation. Its ability to degrade the extracellular matrix enables cancer cell invasion and metastasis. The enzyme also plays a role in inflammatory diseases where it modulates the immune response. Through these disease pathways it relates to other proteins such as matrix metalloproteinases (MMPs) which also participate in matrix remodeling during tumor progression and inflammation.
